Stryker Buys Ortho Oncology Specialist Stanmore Implants
This article was originally published in The Gray Sheet
The approximately $52 million deal increases Stryker's offerings for limb-salvage procedures for cancer patients.
You may also be interested in...
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.
German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.